Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Case Rep Gastrointest Med ; 2017: 1201404, 2017.
Article in English | MEDLINE | ID: mdl-28321345

ABSTRACT

We present an unusual case of a 35-year-old male patient whom a patency capsule stayed in his gut without breaking. He has a history of Peutz-Jeghers syndrome and multiple abdominal surgeries. Prestudy was performed for abdominal searching, but a patency capsule remained in the colon over 9 days. He displayed neither abdominal nor obstructive symptoms in that period. We collected the patency capsule using colonoscopy after dilating a postoperative stricture at an anastomotic site of the rectum. Clinicians should bear in mind that patency capsules may become retained as distally as the colon in patients with a surgical history of the large intestine.

2.
Oncol Lett ; 10(3): 1453-1455, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26622689

ABSTRACT

Benign nodular goiter is a common disease. Although large goiters with obstructive symptoms including shortness of breath and dyspnea are a clear indication for surgery, acute upper airway obstruction, particularly in benign cervical goiter cases, is rare. We herein report the case of 46-year-old female with acute upper airway obstruction due to benign nodular goiter. The patient had a large and elastic goiter which was more pronounced on the left side of her neck, and surgery was scheduled for within a few months. Three months after the initial presentation, while still waiting for surgery, the patient was brought to the emergency room due to loss of consciousness and breathing difficulty and was immediately intubated. A computed tomography (CT) scan revealed that the trachea was markedly compressed by a nodular lesion in the left lobe, and bilateral pneumonia was also evident. Total thyroidectomy was immediately performed via the supraclavicular approach. The patient had an uneventful postoperative course and recovered well. The resected specimen included a well-encapsulated solid and cystic mass. Histopathological examination mainly revealed adenomatous goiter. The present case suggests that benign asymptomatic nodular goiter mostly located in the neck may cause acute airway obstruction, even if the nodules are not large. Early surgery should be performed when tracheal deviation and stenosis due to a large goiter is prominent by CT scan.

3.
Int J Cancer ; 129(10): 2408-16, 2011 Nov 15.
Article in English | MEDLINE | ID: mdl-21207425

ABSTRACT

Lapatinib is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains. EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs). To explore the potential utility of Lapatinib for therapy of ESCC patients, we evaluated the effect of Lapatinib on a panel of ESCC cell lines. EGFR and HER2 expression by the cell lines was established, and the effects of Lapatinib on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated. Additionally, the combined effect of Lapatinib together with Herceptin or Cetuximab on cell-mediated cytotoxicity was evaluated. Lapatinib inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line. Lapatinib also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines. Addition of Lapatinib increased Herceptin-mediated antibody-dependent cell-mediated cytotoxicity by 15-25% with three ESCC target cell lines. Similarly, Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity also increased by 15-30% in two ESCC cell lines on addition of Lapatinib. Cumulatively, the data indicate that Lapatinib has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of Lapatinib and Cetuximab/Herceptin is a promising strategy in ESCC.


Subject(s)
Antibody-Dependent Cell Cytotoxicity/drug effects , Antineoplastic Agents/pharmacology , Cell Proliferation/drug effects , ErbB Receptors/genetics , Esophageal Neoplasms/genetics , Genes, erbB-2 , Neoplasms, Squamous Cell/genetics , Protein Kinase Inhibitors/pharmacology , Quinazolines/pharmacology , Cell Death/drug effects , Cell Line, Tumor , ErbB Receptors/metabolism , Humans , Lapatinib , Neoplasms, Squamous Cell/metabolism , Phosphorylation
4.
Cancer Sci ; 101(9): 1947-54, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20550524

ABSTRACT

Although Th17 cells reportedly play critical roles in the development of autoimmunity and allergic reactions, information on Th17 cells in cancer-bearing hosts is still limited. In the present study, we investigated the distribution of Th17 cells in relation to regulatory T cells (Treg) in the tumor-infiltrating lymphocytes (TILs), regional lymph node lymphocytes, and peripheral blood lymphocytes of gastric cancer patients. Interleukin (IL)-17-producing CD4(+) cells as Th17 cells and CD4(+)CD25(+)FoxP3(+) cells as Treg were evaluated by flow cytometry and expressed as a percentage of the total CD4(+) cells, in addition to performing a Th1/Th2 balance assay. Moreover, immunohistochemical staining for IL-17 and FoxP3 were performed. In TILs from patients with early disease (n = 27), the frequency of Th17 cells was significantly higher than that in the normal gastric mucosa (23.7 ± 8.9 vs 4.5 ± 3.1%). In TILs from patients with advanced disease (n = 28), the frequency of Th17 cells was also significantly higher, but lower compared to early disease, than that in the normal gastric mucosa (15.1 ± 6.2 vs 4.0 ± 2.0%). This observation for Th17 cell-distribution was also confirmed by immunohistochemistry. When the ratio of Th17/Treg in TILs was evaluated in individual cases, it was more markedly increased in early than in advanced disease. In conclusion, the accumulation of Th17 cells as well as Treg in the tumor microenvironment of gastric cancer occurred in early disease and then the infiltration of Th17 cells gradually decreased according to the disease progression, in contrast to increased Treg.


Subject(s)
Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes/immunology , Stomach Neoplasms/immunology , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Aged , Aged, 80 and over , Female , Flow Cytometry , Forkhead Transcription Factors/metabolism , Humans , Immunohistochemistry , Interleukin-17/metabolism , Interleukin-23/metabolism , Interleukins/metabolism , Lymph Nodes/immunology , Lymph Nodes/metabolism , Lymphocytes/metabolism , Lymphocytes, Tumor-Infiltrating/metabolism , Male , Middle Aged , Stomach Neoplasms/blood , Stomach Neoplasms/metabolism , T-Lymphocytes, Regulatory/metabolism , Th1-Th2 Balance , Th17 Cells/metabolism
5.
Dis Esophagus ; 23(5): 422-9, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20002703

ABSTRACT

It has been reported that an increased population of regulatory T cells (T-regs) is one of the reasons for impaired anti-tumor immunity. We investigated the frequency of Foxp3(+) T-regs in tumor-infiltrating lymphocytes (TILs) and peripheral blood lymphocytes (PBLs) of patients with esophageal squamous cell carcinoma (ESCC). Furthermore, in order to elucidate the mechanisms behind T-regs accumulation within tumors, we evaluated the relationship between CCL17 or CCL22 expression and the frequency of Foxp3(+) T-regs. CD4(+)CD25(+)Foxp3(+) T-regs as a percentage of CD4(+) cells were counted by flow cytometry. The frequency of CCL17(+) or CCL22(+) cells among CD14(+) cells in tumors was also evaluated by flow cytometry. Moreover, an in vitro migration assay using T-regs derived from ESCC was performed in the presence of CCL17 or CCL22. The frequency of Foxp3(+) T-regs in TILs was significantly higher than that in the normal esophageal mucosa (24.6 +/- 10.0 vs 7.1 +/- 5.9%, P < 0.01). The frequency of Foxp3(+) T-regs in PBLs of ESCC patients was significantly higher than that in normal healthy donors (7.0 +/- 4.2 vs 2.5 +/- 1.0%, P < 0.01). Furthermore, the frequency of CCL17(+) or CCL22(+) cells among CD14(+) cells within tumors was significantly higher than that of normal esophageal mucosa, and there was a significant correlation between the frequency of CCL17(+) or CCL22(+) cells and Foxp3(+) T-regs in TILs. In addition, the in vitro migration assay indicated that T-regs were significantly induced to migrate by CCL17 or CCL22. In conclusion, CCL17 and CCL22 within the tumor are related to the increased population of Foxp3(+) T-regs in ESCC.


Subject(s)
Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/secondary , Chemokine CCL17/metabolism , Chemokine CCL22/metabolism , Chemotaxis, Leukocyte , Esophageal Neoplasms/immunology , Esophageal Neoplasms/pathology , Forkhead Transcription Factors/immunology , Lymphocytes, Tumor-Infiltrating/immunology , T-Lymphocytes, Regulatory/immunology , Aged , Carcinoma, Squamous Cell/metabolism , Esophageal Neoplasms/metabolism , Female , Forkhead Transcription Factors/metabolism , Humans , Lipopolysaccharide Receptors , Lymphocytes, Tumor-Infiltrating/metabolism , Male , Middle Aged , Neoplasm Metastasis
6.
Anticancer Res ; 29(6): 2137-46, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19528474

ABSTRACT

BACKGROUND: The escape mechanisms leading to trastuzumab-resistance are under investigation, but no report has yet described the mechanisms of escape from trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC). In the present study, the mechanisms of escape from trastuzumab-mediated ADCC were elucidated using esophageal squamous cell carcinoma (SCC) cell clones. MATERIALS AND METHODS: The esophageal SCC cell line TE4, which is highly susceptible to trastuzumab-mediated ADCC, was cloned by limited dilution, resulting in SCC clones with different sensitivities to trastuzumab-mediated ADCC. RESULTS: There was no significant correlation between human epidermal growth factor receptor (HER) 2-expression on the tumor and the sensitivity to trastuzumab-mediated ADCC. Altered major histocompatibility complex (MHC) class I expression treated by IFN-gamma or the blocking of natural killer (NK) cell inhibitory receptors did not induce significant changes in sensitivity to trastuzumab-mediated ADCC. However, the tumor clones with a lower sensitivity to trastuzumab-mediated ADCC showed a reduced susceptibility to the perforin-granzyme system compared to those with a greater sensitivity to trastuzumab-mediated ADCC. CONCLUSION: Lower susceptibility to the perforin-granzyme system is one of the important mechanisms explaining escape from trastuzumab-mediated ADCC.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibody-Dependent Cell Cytotoxicity , Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/immunology , Esophageal Neoplasms/immunology , Granzymes/metabolism , Perforin/metabolism , Antibodies, Monoclonal, Humanized , Apoptosis/drug effects , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/pathology , Flow Cytometry , Humans , Killer Cells, Natural/immunology , Receptor, ErbB-2/immunology , Receptor, ErbB-2/metabolism , Trastuzumab
7.
Cancer Sci ; 100(8): 1502-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19459850

ABSTRACT

We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three cancer-testis antigens, TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3), as targets for cancer vaccination against esophageal squamous cell carcinoma (ESCC). To examine the safety, immunogenicity, and antitumor effect of vaccine treatment using a combination of these three peptides, 10 HLA-A2402-positive advanced ESCC patients who failed to standard therapy were enrolled in a phase I clinical trial. Each of the three peptides (1 mg each) was intradermally administered with 1 mL of incomplete Freund's adjuvant to the neck in three separate regions weekly for 5 weeks. The cancer vaccination therapy was well tolerated without any treatment-associated adverse events of grade 3 or 4. The TTK-, LY6K-, and/or IMP-3-specific T-cell immune responses were observed by enzyme-linked immunospot assay in peripheral blood lymphocytes obtained from nine of the 10 ESCC patients after their vaccination. The median survival time after the vaccination was 6.6 months. The vaccination could induce good clinical responses in 50% of the 10 patients. One patient experienced a complete response in hepatic metastasis lasting 7 months, one showed objective responses in all lung metastasis lesions, and three patients revealed a stable disease condition for at least 2.5 months. The cancer vaccine therapy using these three peptides demonstrated satisfactory safety and good immunogenicity as well as promising disease control rate, and therefore warrants further clinical studies.


Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Carcinoma, Squamous Cell/immunology , Esophageal Neoplasms/immunology , Peptide Fragments/immunology , Aged , Cancer Vaccines/adverse effects , Feasibility Studies , Female , Follow-Up Studies , Freund's Adjuvant/immunology , HLA-A Antigens/immunology , HLA-A24 Antigen , Humans , Kaplan-Meier Estimate , Lipids/immunology , Male , Middle Aged , Survival Analysis , T-Lymphocytes/immunology , Time Factors , Treatment Outcome , Vaccination
8.
Oncology ; 74(3-4): 143-9, 2008.
Article in English | MEDLINE | ID: mdl-18708731

ABSTRACT

BACKGROUND AND METHODS: It has been shown that T-cell dysfunction, including apoptosis of peripheral blood T cells, commonly occurs in patients receiving chemotherapy. In order to evaluate whether concomitant administration of the oral biological response modifier protein-bound polysaccharide K (PSK) could induce anti-apoptotic effects in patients treated with the anti-cancer drug, S-1, peripheral blood T cells were analyzed for induction of apoptosis, caspase-3 activities and expression of proapoptotic protein Bax and anti-apoptotic protein Bcl-2 in patients with curatively resected stage III gastric cancer, who were randomly assigned to postoperative adjuvant therapy with S-1 alone (n = 10) or S-1 combined with PSK (n = 10). RESULTS: T-cell apoptosis 5 weeks after adjuvant therapy was significantly higher in the S-1 group (24.1 +/- 5.0%) than in the S-1 + PSK group (19.1 +/- 3.9%). S-1 induced T-cell apoptosis and concomitantly elevated caspase-3 activities and Bax expression in peripheral blood T cells. In addition, PSK partially prevented the T-cell apoptosis induced by S-1. CONCLUSION: PSK could partially prevent the T-cell apoptosis induced by S-1.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Apoptosis/drug effects , Oxonic Acid/therapeutic use , Proteoglycans/therapeutic use , Stomach Neoplasms/drug therapy , T-Lymphocytes/drug effects , Tegafur/therapeutic use , Aged , Caspases/metabolism , Chemotherapy, Adjuvant , Drug Combinations , Drug Therapy, Combination , Female , Flow Cytometry , Humans , Male , Proto-Oncogene Proteins c-bcl-2/metabolism , Stomach Neoplasms/blood , Stomach Neoplasms/pathology , T-Lymphocytes/metabolism , bcl-2-Associated X Protein/metabolism
9.
Cancer Sci ; 99(7): 1448-54, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18452554

ABSTRACT

We recently identified three HLA-A2402-restricted epitope peptides derived from cancer-testis antigens (CTA), TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3) for the development of immunotherapies against esophageal squamous cell carcinoma (ESCC). In order to evaluate their immunotherapeutic potential in ESCC patients, we estimated by ELISPOT assay the TTK-, LY6K-, or IMP-3-specific T-cell immune responses in tumor-infiltrating lymphocytes (TIL), regional lymph node lymphocytes (RLNL), and peripheral blood lymphocytes (PBL) expanded from 20HLA-A2402 (+) ESCC patients, and correlated their immune activity with the expression levels of TTK, LY6K, and IMP-3, and MHC class I in the tumors. Induction of TTK-antigen specific T-cell response in TIL to the peptide-pulsed target cells was detected in 14 out of 20 (70%) cases, while LY6K or IMP-3 specific T-cell activity was observed in 11 of 20 (55%) or in eight of 20 (40%) cases, respectively. Furthermore, T-cell activity in RLNL and PBL was detectable in the similar proportion of the 20 ESCC patients. Interestingly, CTA-specific T-cell immune response was found in 13 of 14 (93%) TIL obtained from ESCC tumors with strong MHC class I expression, while it could be observed only in two of six (33%) TIL from ESCC tumors with weak MHC class I expression. These results strongly suggest the pre-existence of specific T-cell responses to HLA-A24-restricted epitope peptides from TTK, LY6K, and IMP-3 in ESCC patients. Monitoring antigen-specific T-cell responses, as well as the expression levels of MHC class I and epitope CTA in tumors, should be a selection index for application of cancer vaccine therapies to the patients who are likely to show good immune response.


Subject(s)
Antigens, Ly/immunology , Carcinoma, Squamous Cell/immunology , Cell Cycle Proteins/immunology , Esophageal Neoplasms/immunology , Lymph Nodes/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Neoplasm Proteins/immunology , Protein Serine-Threonine Kinases/immunology , RNA-Binding Proteins/immunology , Aged , Antigens, Ly/analysis , Cell Cycle Proteins/analysis , Cell Line , GPI-Linked Proteins , Histocompatibility Antigens Class I/analysis , Humans , Male , Middle Aged , Neoplasm Proteins/analysis , Protein Serine-Threonine Kinases/analysis , Protein-Tyrosine Kinases , RNA-Binding Proteins/analysis
10.
Int J Cancer ; 122(10): 2286-93, 2008 May 15.
Article in English | MEDLINE | ID: mdl-18224687

ABSTRACT

It has been reported that an increased population of regulatory T cells (Tregs) is one of the reasons for impaired anti-tumor immunity. Recently, Foxp3 has been reported as a reliable marker of Tregs. The authors investigated the frequency of Foxp3(+) Tregs within CD4(+) cells in TILs, regional lymph nodes and PBLs of gastric cancer patients (n = 45). Furthermore, to elucidate the mechanisms behind Treg accumulation within tumors, they evaluated the relationship between CCL17 or CCL22 expression and the frequency of Foxp3(+) Tregs in gastric cancer. CD4(+)CD25(+)Foxp3(+) Tregs as a percentage of CD4(+) cells were counted by flow cytometry and evaluated by immunohistochemistry. Moreover, an in vitro migration assay using Tregs derived from gastric cancers was performed in the presence of CCL17 or CCL22. As a result, the frequency of Foxp3(+) Tregs in TILs was significantly higher than that in normal gastric mucosa (12.4% +/- 7.5% vs. 4.1% +/- 5.3%, p < 0.01). Importantly, the increase in Tregs in TILs occurred to the same extent in early and advanced disease. Furthermore, the frequency of CCL17(+) or CCL22(+) cells among CD14(+) cells within tumors was significantly higher than that of normal gastric mucosa, and there was a significant correlation between the frequency of CCL17(+) or CCL22(+) cells and Foxp3(+) Tregs in TILs. In addition, the in vitro migration assay indicated that Tregs were significantly induced to migrate by CCL17 or CCL22. In conclusion, CCL17 and CCL22 within the tumor are related to the increased population of Foxp3(+) Tregs, with such an observation occurring in early gastric cancer.


Subject(s)
Chemokine CCL17/metabolism , Chemokine CCL22/metabolism , Forkhead Transcription Factors/metabolism , Stomach Neoplasms/immunology , T-Lymphocytes, Regulatory/immunology , Aged , CD28 Antigens/metabolism , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Cell Movement , Female , Gastric Mucosa/immunology , Humans , Immunoenzyme Techniques , Lymph Nodes/pathology , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/pathology , Male , T-Lymphocytes, Regulatory/pathology
11.
Oncology ; 72(3-4): 172-80, 2007.
Article in English | MEDLINE | ID: mdl-18097168

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) is produced by almost all cancer cells and VEGF receptor 1 (R1) (Flt-1) is abundantly expressed on human monocytes. In the present study, we investigated whether VEGF affects the antibody-dependent cell-mediated cytotoxicity (ADCC) of human monocytes mediated by trastuzumab. METHODS: HER-2-expressing tumor cell lines (MKN-7, TE-4 and SKOV-3) were evaluated for trastuzumab-mediated ADCC of human monocytes in the presence of VEGF(165). The trastuzumab-mediated, monocyte-derived ADCC were treated with the anti-human blocking VEGF R1 or VEGF R2 mAb. VEGF-induced intracellular signaling on monocytes was quantified with ELISA kits. RESULTS: VEGF partially inhibited the ADCC of human monocytes mediated by trastuzumab. The VEGF-induced deficiency of human monocytes for ADCC was completely recovered by the anti-human blocking VEGF R1 mAb, while the anti-VEGF R2 blocking mAb did not have any effect. Furthermore, VEGF treatment enhanced the phospho-Erk 1/2 in human monocytes. CONCLUSION: VEGF partially inhibited the ADCC of human monocytes mediated by trastuzumab, and this inhibition was mainly mediated by VEGF R1 (Flt-1).


Subject(s)
Angiogenesis Inducing Agents/pharmacology , Antibodies, Monoclonal/pharmacology , Antibody-Dependent Cell Cytotoxicity/drug effects , Antineoplastic Agents/pharmacology , Monocytes/drug effects , Vascular Endothelial Growth Factor A/pharmacology , Antibodies, Monoclonal, Humanized , Cell Line, Tumor , Genes, erbB-2 , Humans , Monocytes/immunology , Trastuzumab
SELECTION OF CITATIONS
SEARCH DETAIL
...